23-Mar-2020 | Facts and Factors
Findings from Facts and Factors report “Acromegaly and Gigantism Drugs Market By Type (GH Receptor Antagonists, Somatostatin Analogs, Dopamine Agonists, and Others), By Treatment (Medication, Radiation Therapy, and Surgery), and By End-Use (Clinics, Hospitals, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global acromegaly and gigantism drugs market in 2019 was approximately USD 709.5 Million. The market is expected to grow above a CAGR of 3.5% and is anticipated to reach over USD 902.6 Million by 2026.
Acromegaly is an irregular developmental condition caused by excessive growth hormone production in adults. The condition of acromegaly is usually caused by a pituitary tumor. The term acro implies limbs and megaly implies the expansion of; hence acromegaly refers to feet and hands and expansion. Gigantism is also a metabolic disease caused by the overdevelopment of growth hormones during the teenage years. The disease is characterized by overgrowth of irregular height and bone. Acromegaly and gigantism are considered serious and life-threatening conditions.
Browse the full “Acromegaly and Gigantism Drugs Market By Type (GH Receptor Antagonists, Somatostatin Analogs, Dopamine Agonists, and Others), By Treatment (Medication, Radiation Therapy, and Surgery), and By End-Use (Clinics, Hospitals, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/acromegaly-and-gigantism-drugs-market-by-type-gh-891
GH-related diseases are acromegaly and gigantism. Gigantism occurs in infants, while acromegaly diseases occur in adults. The report provides an overview of the market categorized on the basis of drug class, GH receptor antagonists, somatostatin analogs, recombinant human IGF-1, dopamine agonists Scientists concentrate on starting acromegaly and gigantism pipeline particles, and most of these particles are at phase III stage of development. While focusing more on the production of medications, different companies are trying to satisfy the medical requirements for this condition.
The drug class of somatostatin analogs accounted for the largest market share. The analysis will also provide a reliable estimate of the contribution of the different segments of the drug class to the development of the market size of acromegaly and gigantism drugs. Due to the low success rate of acromegaly surgical procedures, the market for semi-surgical options and the prevalence of pharmacological treatments for acromegaly are steadily increasing. This is one of the key factors that will boost the market size and share of acromegaly and gigantism drugs. Just four of the 310 subjects approved to be treated with a trans-sphenoidal procedure were found to have been healed. In addition, there was also a deficiency of postoperative anterior pituitary cortisol in approximately 10 participants. Due to the lack of trained surgeons and pituitary surgical sites, the demand for drug treatment to cure the disease will continue to increase.
It is anticipated that North America will dominate the global market during the forthcoming years. The growing prevalence of pituitary tumors in the region has contributed to acromegaly and gigantism and is one of the key drivers of market growth in the region. In addition, advancing technology, high spending on health care, increased awareness among people about disease treatment, etc. are some of the factors directly related to market growth in North America. Europe is also expected to hold a significant share of the world market on the basis of factors such as continued investment in healthcare in the region, focus on new entrants, etc. The Asia-Pacific market is expected to grow faster during the forecast period. The Asia Pacific is projected to have the most lucrative business by introducing health care strategies for a better quality of life, increasing health education, and rising healthcare spending, etc.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 709.5 Million |
Projected Market Size in 2026 |
USD 902.6 Million |
CAGR Growth Rate |
3.5% CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Pfizer Inc., Ionis Pharmaceuticals Inc., Chiasma, Inc., Novartis AG, Crinetics Pharmaceuticals, Ipsen, Midatech Pharma Plc, Novartis AG, and others. |
Key Segment |
By Drug, Treatment, End-Use, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Top key players operating in the market are Pfizer Inc., Ionis Pharmaceuticals Inc., Chiasma, Inc., Novartis AG, Crinetics Pharmaceuticals, Ipsen, Midatech Pharma Plc, Novartis AG, and Others.
This report segments the acromegaly and gigantism drugs market as follows:
Global Acromegaly and Gigantism Drugs Market: By Drug Type Segmentation Analysis
- GH Receptor Antagonists
- Somatostatin Analogs
- Dopamine Agonists
- Others
Global Acromegaly and Gigantism Drugs Market: By Treatment Segmentation Analysis
- Medication
- Radiation Therapy
- Surgery
Global Acromegaly and Gigantism Drugs Market: By End-Use Segmentation Analysis
Global Acromegaly and Gigantism Drugs Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
